Inclusion Criteria:

- Histologically or cytologically confirmed advanced solid malignancies that are
metastatic or unresectable, and for which standard/curative measures do not exist by
RECIST 1.1 measureable lesion which is not declining

- Age ≥ 18 years old at the day of consenting to the study

- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2

- Adequate bone marrow and organ function as defined by laboratory values

Exclusion Criteria:

- Previous treatment with PI3K inhibitors

- Concurrent malignancy or has a malignancy within 3 years of study enrollment, (with
the exception of adequately treated basal or squamous cell carcinoma or cervical
carcinoma in situ)

- Concurrently using other approved or investigational antineoplastic agent

- Currently receiving anticancer therapies or who have received anticancer therapies
within 4 weeks of the start of study drug (including chemotherapy, radiation therapy,
antibody based therapy, hormonal therapy, etc.)

- Poorly controlled diabetes mellitus (HbA1c > 8 %)

- Chronic treatment with systemic steroids or another immunosuppressive agent

- Active cardiac disease

- Inadequately controlled hypertension (i.e, SBP >180 mmHg or DBP >100mmHg)

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of BEZ235 (e.g., ulcerative diseases, uncontrolled nausea,
vomiting, diarrhea grade ≥ 2, malabsorption syndrome, or small bowel resection)